Vascular Biogenics Ltd. (VBLT)
| Market Cap | 83.85M |
| Revenue (ttm) | 777,000 |
| Net Income (ttm) | -28.07M |
| Shares Out | 69.30M |
| EPS (ttm) | -0.47 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 73,423 |
| Open | 1.22 |
| Previous Close | 1.21 |
| Day's Range | 1.19 - 1.25 |
| 52-Week Range | 1.13 - 3.17 |
| Beta | 1.06 |
| Analysts | Buy |
| Price Target | 5.50 (+354.5%) |
| Earnings Date | n/a |
About VBLT
Vascular Biogenics Ltd., a clinical biopharmaceutical company, focuses on the discovery, development, and commercialization of treatments for cancer and immune/inflammatory indications in Israel and the United States. The company's program is based on its proprietary vascular targeting system platform technology, which utilizes genetically targeted therapy to destroy newly formed or angiogenic blood vessels. Its lead product candidate is VB-111, a gene-based biologic that is in Phase III clinical trials for the recurrent platinum-resistant ovar...
Financial Performance
Financial StatementsAnalyst Forecast
According to 3 analysts, the average rating for VBLT stock is "Buy." The 12-month stock price forecast is 5.50, which is an increase of 354.55% from the latest price.
News
VBL Therapeutics Announces Appointment of Matthew Trudeau as Chief Commercial Officer
TEL AVIV, Israel and NEW YORK, Jan. 18, 2022 (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq: VBLT), a late-clinical stage biotechnology company developing first-in-class therapeutics for difficult-to-trea...
VBL Therapeutics to Present at H.C. Wainwright BioConnect Virtual Conference
TEL AVIV, Israel and NEW YORK, Jan. 06, 2022 (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq: VBLT), a clinical stage biotechnology company developing first-in-class therapeutics for difficult-to-treat mal...
VBL Therapeutics Selected for €17.5 Million of Funding from Horizon Europe EIC Accelerator Program
VBL is among only 9% of companies across industries selected by the EIC Accelerator
What Makes Vascular Biogenics (VBLT) a New Buy Stock
Vascular Biogenics (VBLT) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Vascular Biogenics (VBLT) Reports Q3 Loss, Lags Revenue Estimates
Vascular Biogenics (VBLT) delivered earnings and revenue surprises of 10.00% and -0.50%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?
VBL Therapeutics Reports Third Quarter 2021 Financial Results and Provides Corporate Update
Conference Call and Webcast at 8:30 a.m. ET Today
Will Vascular Biogenics (VBLT) Report Negative Q3 Earnings? What You Should Know
Vascular Biogenics (VBLT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
VBL Therapeutics to Report Third Quarter Financial Results on November 15
TEL AVIV, Israel and NEW YORK, Nov. 08, 2021 (GLOBE NEWSWIRE) -- VB L Therape u tics (Nasdaq: VBLT ), a clinical stage company developing first-in-class therapeutics for difficult-to-treat malignant so...
VBL Therapeutics Announces Appointment of Sam Backenroth as Chief Financial Officer and Establishes Operations in the...
Amos Ron to Retire as CFO and Will Continue to Serve as Corporate Secretary, Advisor to VBL Amos Ron to Retire as CFO and Will Continue to Serve as Corporate Secretary, Advisor to VBL
VBL Therapeutics Announces Independent Data Safety Monitoring Committee Provides Clearance to Continue the OVAL Phase...
TEL AVIV, Israel, Sept. 17, 2021 (GLOBE NEWSWIRE) -- VBL Therapeutics (NASDAQ: VBLT) today announced that the independent Data Safety Monitoring Committee (DSMC) of the ongoing OVAL Phase 3 registration...
VBL Therapeutics to Present at Upcoming Conferences
TEL AVIV, Israel, Sept. 10, 2021 (GLOBE NEWSWIRE) -- VBL Therapeutics (NASDAQ: VBLT) today announced the Company will present in the following upcoming industry conferences:
VBL Therapeutics Resumes U.S. Enrollment in OVAL Phase 3 Trial as FDA Authorizes Clinical Use of VB-111 Batches Produ...
TEL AVIV, Israel, Aug. 30, 2021 (GLOBE NEWSWIRE) -- VBL Therapeutics (NASDAQ: VBLT) today announced enrollment of new patients in VB-111 studies in the Unites States will resume immediately following au...
Vascular Biogenics (VBLT) Reports Q2 Loss, Lags Revenue Estimates
Vascular Biogenics (VBLT) delivered earnings and revenue surprises of -20.00% and -48.63%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?
VBL Therapeutics Reports Second Quarter 2021 Financial Results and Provides Corporate Update
Conference Call and Webcast at 8:30 a.m. EDT Today
Will Vascular Biogenics (VBLT) Report Negative Q2 Earnings? What You Should Know
Vascular Biogenics (VBLT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
VBL Therapeutics to Report Second Quarter Financial Results on August 16
TEL AVIV, Israel, Aug. 05, 2021 (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq: VBLT) will release its second quarter financial results for the period ended June 30, 2021 on Monday, August 16 before marke...
VBL Therapeutics Appoints Marc Kozin as Chairman of its Board of Directors
TEL AVIV, Israel, July 22, 2021 (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq: VBLT) today announced the planned elevation of Marc Kozin as chairman of the company's board of directors. Bennett Shapiro, ...
VBL Therapeutics Appoints Alison Finger and Michael Rice to its Board of Directors
TEL AVIV, Israel, July 08, 2021 (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq: VBLT) today announced the appointments of Alison Finger and Michael Rice to its Board of Directors, effective July 7, 2021. ...
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Vascular Biogenics Ltd. - VBLT
NEW YORK, June 16, 2021 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Vascular Biogenics Ltd. ("VBL" or the "Company") (NASDAQ: VBLT).
VBL Therapeutics Shares Drop As Pending Clearance Of New Batches Cancer Gene Therapy Hit Recruitment In Ovarian Cance...
The FDA notified VBL Therapeutics Ltd (NASDAQ: VBLT) that clearance of new VB-111 batches for use in the U.S. is currently pending, as review by the Chemistry, Manufacturing, and Controls (CMC) group is...
VBL Therapeutics Announces Addition of Progression Free Survival as a Second Primary Endpoint in OVAL, a Phase 3 Regi...
TEL AVIV, Israel, June 03, 2021 (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq: VBLT) today announced a primary endpoint amendment in the OVAL Phase 3 registration-enabling study of VB-111. The clinical t...
VBL Therapeutics to Provide an Update on the OVAL Phase 3 Registration Enabling Study of VB-111 in Ovarian Cancer at ...
TEL AVIV, Israel, May 20, 2021 (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq: VBLT) today announced that a poster providing an update on the OVAL Phase 3 registration enabling clinical trial of VB-111 in...
Vascular Biogenics (VBLT) Reports Q1 Loss, Lags Revenue Estimates
Vascular Biogenics (VBLT) delivered earnings and revenue surprises of 7.69% and -7.50%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?
VBL Therapeutics Reports First Quarter 2021 Financial Results and Provides Corporate Update
Conference Call and Webcast at 8:30 a.m. EDT Today
Vascular Biogenics's Earnings: A Preview
Vascular Biogenics (NASDAQ:VBLT) announces its next round of earnings this Tuesday, May 11. Here is Benzinga's everything-that-matters guide for this Tuesday's Q1 earnings announcement.